Interactions of commonly used dietary supplements with cardiovascular drugs: A systematic review

Systematic Reviews

Volumn 1, Issue 1, 2012, Pages

  Kanji, Salmaan ^a   Seely, Dugald ^a,b   Yazdi, Fatemeh ^a   Tetzlaff, Jennifer ^a   Singh, Kavita ^a   Tsertsvadze, Alexander ^a   Tricco, Andrea C ^c   Sears, Margaret E ^a,d   Ooi, Teik C ^e   Turek, Michele A ^e   Skidmore, Becky ^e   Ansari, Mohammed T ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cardiovascular drugs; Dietary supplements; Harms; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALPHA TOCOPHEROL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECHINACEA EXTRACT; FENOFIBRATE; FISH OIL; FUROSEMIDE; GARLIC EXTRACT; GEMFIBROZIL; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; NICOTINIC ACID; NIFEDIPINE; NITRATE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; TICLOPIDINE; TRIACYLGLYCEROL; UBIDECARENONE; UNINDEXED DRUG; WARFARIN;

ARTICLE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; HYPERTRIGLYCERIDEMIA; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; DRUG INTERACTION; REVIEW;

CARDIOVASCULAR AGENTS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; HUMANS;

MLCS; MLOWN;

EID: 84876161854     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-26     Document Type: Article

References (110)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circ Cardiovasc Qual Outcomes 2010, 121:e46-e215.
2. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 2011, 8:253-265.
3. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52:1769-1781.
4. Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Shrank WH. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011, 171:814-822.
5. Nahin RL, Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States. Natl Health Stat Report 2007, 2009:1-14.
6. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol 2006, 98:673-680.
7. Zick SM, Blume A, Aaronson KD. The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail 2005, 11:586-589.
8. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010, 55:515-525.
9. Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med 1998, 158:2225-2234.
10. Maraldi C, Lattanzio F, Onder G, Gallerani M, Bustacchini S, De TG, Volpato S. Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations. Drugs Aging 2009, 26(Suppl 1):41-51.
11. Garner JB. Problems of nonadherence in cardiology and proposals to improve outcomes. Am J Cardiol 2010, 105:1495-1501.
12. Miller KL, Liebowitz RS, Newby LK. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J 2004, 147:401-411.
13. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 2008, 9:1063-1120.
14. The Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov/index.cfm.
15. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized?. Trials 2009, 10:46.
16. Shekelle PG, Morton SC, Suttorp MJ, Buscemi N, Friesen C. Challenges in systematic reviews of complementary and alternative medicine topics. Ann Intern Med 2005, 142:1042-1047.
17. Halsted CH. Dietary supplements and functional foods: 2 sides of a coin?. Am J Clin Nutr 2003, 77:1001S-1007S.
18. Coppens P, da Silva MF, Pettman S. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology 2006, 221:59-74.
19. Eberhardie C. Nutritional supplements and the EU: is anyone happy?. Proc Nutr Soc 2007, 66:508-511.
20. US Food and Drug Administration Overview of Dietary Supplements. http://www.fda.gov/food/dietarysupplements/consumerinformation/ucm110417.htm, US Food and Drug Administration.
21. Pharand C, Ackman ML, Jackevicius CA, Paradiso-Hardy FL, Pearson GJ. Canadian Cardiovascular Pharmacists Network: Use of OTC and herbal products in patients with cardiovascular disease. Ann Pharmacother 2003, 37:899-904.
22. Gohar F, Greenfield SM, Gareth BD, Lip GYH, Jolly K. Self-care and adherence to medication: a survey in the hypertension outpatient clinic. BMC Complement Altern Med 2008, 8:4.
23. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and mineral supplement use in the United States: results from the third national health and nutrition examination survey. Arch Fam Med 2000, 9:258-262.
24. Schellhorn B, Doring A, Stieber J. Use of vitamin and mineral supplements: Results from the survey 1994/95 of the WHO MONICA Project Augsburg. Z Ernährungswiss 1998, 37:198-206.
25. Nahin RL, Pecha M, Welmerink DB, Sink K, DeKosky ST, Fitzpatrick AL. Ginkgo Evaluation of Memory Study Investigators: Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009, 57:1197-1205.
26. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Report 2007, 2008:1-23.
27. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circ Cardiovasc Qual Outcomes 2004, 110:227-239.
28. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Chang S, Helfand M. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol 2010, 63:513-523.
29. Atkins D, Chang SM, Gartlehner G, Buckley DI, Whitlock EP, Berliner E, Matchar D. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol 2011, 64:1198-1207.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
31. Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, Griffith L, Oremus M, Raina P, Ismaila A, Santaguida P, Lau J, Trikalinos TA. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol 2011, 64(11):1187-1197.
32. US Food and Drugs Administration Approved drug products with therapeutic equivalence evaluations 2011, Silver Spring (MD): US Food and Drug Administration, US Food and Drugs Administration.
33. Takkouche B, Etminan M, Caamano F, Rochon PA. Interaction between aspirin and ACE Inhibitors: resolving discrepancies using a meta-analysis. Drug Saf 2002, 25:373-378.
34. The Agency for Healthcare Research and Quality Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm. Last Accessed: 8-3-2012, The Agency for Healthcare Research and Quality.
35. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta analysis 2005, Englewood NJ, Version 2.2.057.
36. StatsDirect Ltd StatsDirect statistical software 2012, UK: Altrincham, StatsDirect Ltd.
37. Di Spirito M, Morelli G, Doyle RT, Johnson J, McKenney J. Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin Pharmacother 2008, 9:2939-2945.
38. Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008, 102:429-433. Erratum appears inAm J Cardiol2008; 102(10):1425..
39. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, Scott RS. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007, 100:1400-1403.
40. Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circ Cardiovasc Qual Outcomes 2007, 116:1497-1503.
41. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367.
42. Miyamoto S, Kawano H, Takazoe K, Soejima H, Sakamoto T, Hokamaki J, Yoshimura M, Nakamura H, Yodoi J, Ogawa H. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina. Thromb Res 2004, 113:345-351.
43. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002, 32:429-436.
44. Motoyama T, Kawano H, Kugiyama K, Hirashima O, Ohgushi M, Tsunoda R, Moriyama Y, Miyao Y, Yoshimura M, Ogawa H, Yasue H. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. J Am Coll Cardiol 1998, 32:1672-1679.
45. Napoli C, Leccese M, Palumbo G, De NF, Chiariello P, Zuliani P, Somma P, Di LM, De MC, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento FP. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis 1998, 9:257-264.
46. Eritsland J, Arnesen H, Nseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996, 77:31-36.
47. Garg RK, Nag D, Agrawal A. A double blind placebo controlled trial of ginkgo biloba extract in acute cerebral ischaemia. J Assoc Phys India 1995, 43:760-763.
48. Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995, 62:1381S-1384S.
49. Yamamoto H, Yoshimura H, Noma M, Suzuki S, Kai H, Tajimi T, Sugihara M, Kikuchi Y. Improvement of coronary vasomotion with eicosapentaenoic acid does not inhibit acetylcholine-induced coronary vasospasm in patients with variant angina. Jpn Circ J 1995, 59:608-616. Erratum appears inJpn Circ J1995, 59(11):773-774..
50. Kaul U, Sanghvi S, Bahl VK, Dev V, Wasir HS. Fish oil supplements for prevention of restenosis after coronary angioplasty. Int J Cardiol 1992, 35:87-93.
51. Dehmer GJ, Popma JJ, van den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988, 319:733-740.
52. Liu M, Wallmon A, Wallin R, Saldeen T. Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia. Nutr Res 2003, 23:1027-1034.
53. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999, 33:1549-1552.
54. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998, 5:257-261.
55. Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol 2009, 54:196-203.
56. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003, 168:169-179.
57. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J, Hokuriku Lipid Research Group Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis 2007, 195:e182-e189. Hokuriku Lipid Research Group.
58. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
59. Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006, 136:793S-795S.
60. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008, 154:1691-1700.
61. Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998, 58:257-263.
62. Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, Rosen RT, Amagase H. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med 2004, 39:985-991.
63. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005, 59:425-432.
64. Wolf HR. DoesGinkgo bilobaspecial extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?. Drugs in R D 2006, 7:163-172.
65. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect ofGinkgo biloba(EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis 2007, 18:787-793.
66. Kim BH, Kim KP, Lim KS, Kim JR, Yoon SH, Cho JY, Lee YO, Lee KH, Jang IJ, Shin SG, Yu KS. Influence ofGinkgo bilobaextract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010, 32:380-390.
67. Aruna D, Naidu MU. Pharmacodynamic interaction studies ofGinkgo bilobawith cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007, 63:333-338.
68. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin andPanax ginsengin ischemic stroke patients. J Altern Complement Med 2008, 14:715-721.
69. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004, 141:23-27.
70. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004, 57:592-599. [Erratum appears in Br J Clin Pharmacol 2004, 58(1):102.
71. Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaronson KD, Bleske BE. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003, 43:637-642.
72. Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010, 85:122-128.
73. Nordøy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 2000, 20:259-265.
74. Meyer BJ, Hammervold T, Rustan AC, Howe PR. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids 2007, 42:109-115.
75. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol 1997, 80:797-798.
76. Nordøy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 2003, 1:690-697.
77. Isley WL, Miles JM, Harris WS. Pilot study of combined therapy with omega-3 fatty acids and niacin in atherogenic dyslipidemia. J Clin Lipidol 2007, 1:211-217.
78. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2009, 24:156-160.
79. Howe PR, Lungershausen YK, Cobiac L, Dandy G, Nestel PJ. Effect of sodium restriction and fish oil supplementation on BP and thrombotic risk factors in patients treated with ACE inhibitors. J Hum Hypertens 1994, 8:43-49.
80. Svaneborg N, Kristensen SD, Hansen LM, Llow I, Husted SE, Schmidt EB. The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids. Thromb Res 2002, 105:311-316.
81. Balestrieri GP, Maffi V, Sleiman I, Spandrio S, Di SO, Salvi A, Scalvini T. Fish oil supplementation in patients with heterozygous familial hypercholesterolemia. Recenti Prog Med 1996, 87:102-105.
82. Hansen JB, Lyngmo V, Svensson B, Nord YA. Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa). Rterioscler Thromb 1993, 13:98-104.
83. McKenney JM, Swearingen D, Di SM, Doyle R, Pantaleon C, Kling D, Shalwitz RA. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006, 46:785-791.
84. Mueller BA, Talbert RL, Tegeler CH, Prihoda TJ. The bleeding time effects of a single dose of aspirin in subjects receiving omega-3 fatty acid dietary supplementation. J Clin Pharmacol 1991, 31:185-190.
85. Lungershausen YK, Howe PR. Improved detection of a blood pressure response to dietary intervention with 24-hour ambulatory monitoring. Am J Hypertens 1994, 7:1115-1117.
86. Micheletta F, Natoli S, Misuraca M, Sbarigia E, Diczfalusy U, Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque. Arterioscler Thromb Vasc Biol 2004, 24:136-140.
87. Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G. Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension 1999, 34:1002-1006.
88. Sutken E, Inal M, Ozdemir F. Effects of vitamin E and gemfibrozil on lipid profiles, lipid peroxidation and antioxidant status in the elderly and young hyperlipidemic subjects. Saudi Med J 2006, 27:453-459.
89. Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, Santucci A, Ferri C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab 2003, 88:5341-5347.
90. Manuel YK, Vinckx M, Vertommen J, Van GL, De Leeuw I. Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. Atherosclerosis 2004, 175:369-376.
91. Duffy SJ, O'Brien RC, New G, Harper RW, Meredith IT. Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study. Clin Exp Pharmacol Physiol 2001, 28:409-418.
92. McDowell IF, Brennan GM, McEneny J, Young IS, Nicholls DP, McVeigh GE, Bruce I, Trimble ER, Johnston GD. The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. Eur J Clin Invest 1994, 24:759-765.
93. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, Mezzetti A, Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circ Cardiovasc Qual Outcomes 2002, 106:2543-2549.
94. Paolisso G, Gambardella A, Giugliano D, Galzerano D, Amato L, Volpe C, Balbi V, Varricchio M, D'Onofrio F. Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. Am J Clin Nutr 1995, 61:848-852.
95. D'Arcangues C, Piaggio G, Brache V, Aissa RB, Hazelden C, Massai R, Pinol A, Subakir SB, Su-juan G, Study Group on Progestogen-induced Vaginal Bleeding Disturbances Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004, 70:451-462. Study Group on Progestogen-induced Vaginal Bleeding Disturbances.
96. Gosai P, Liu J, Doyle RT, Johnson J, Carter R, Sica D, McKenney JM. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin Pharmacother 2008, 9:2947-2953.
97. Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, Matthias A, Lehmann RP, McLachlan AJ. Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 2010, 69:508-515.
98. Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact ofGinkgo bilobaon the pharmacokinetics of digoxin. Am J Ther 2003, 10:247-251.
99. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel-versus-aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol 2009, 104:1052-1054.
100. Seely D, Kanji S, Yazdi F, Tetzlaff J, Singh K, Tsertsvadze A, Sears M, Tricco A, Ooi TC, Turek M, Tsouros S, Skidmore B, Daniel R, Ansari M. Dietary supplements in adults taking cardiovascular drugs 2012, Rockville, MD: Agency for Healthcare Research and Quality, Publication No.12-EHC021-EF.
101. Foundation for Statistical Computing R: a language and environment for statistical computing 2011, Vienna, Austria, Foundation for Statistical Computing.
102. Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010, 41:729-735.
103. Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman RR. Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial. Atherosclerosis 2010, 213:512-517.
104. FDA should take further actions to improve oversight and consumer understanding. http://www.gao.gov/products/GAO-09-250.
105. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: A systematic review of clinical trials. Ther Drug Monit 2005, 27:549-557.
106. Desai D, Hasan A, Wesley R, Sunderland E, Pucino F, Csako G. Effects of dietary supplements on aspirin and other antiplatelet agents: an evidence-based approach. Thromb Res 2005, 117:87-101.
107. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005, 98:1-14.
108. Skalli S, Zaid A, Soulaymani R. Drug interactions with herbal medicines. Ther Drug Monit 2007, 29:679-686.
109. Kennedy DA, Seely D. Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf 2010, 9:79-124.
110. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997, 350:326-329.